Influenza Therapy

ImmuneRegen BioSciences: Viprovex is a potential treatment for avian and other influenzas

Published in Drug Law Weekly, February 6th, 2007

ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc., (IRBO), announced results from tests conducted using Viprovex, its proprietary compound, in a severe influenza treatment study.

Tests evaluating ImmuneRegen's Viprovex as a measure in the possible treatment of influenza virus infection were conducted at Virion Systems, Inc., (VSI), a Maryland biotechnology corporation. Influenza studies were performed using a cotton rat (Sigmodon hispidus) model system with the influenza A/Wuhan/359/95 (H3N2), a robust, peer-reviewed model system for studying human influenza.

Management believes preliminary results of Viprovex...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Law Weekly

Source: Drug Law Weekly (2007-02-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry